Allarity Therapeutics Files 8-K
Ticker: ALLR · Form: 8-K · Filed: Mar 20, 2024 · CIK: 1860657
Sentiment: neutral
Topics: material-agreement
TL;DR
Allarity Therapeutics filed an 8-K on 3/19/24, likely a material agreement, but details are scarce.
AI Summary
On March 19, 2024, Allarity Therapeutics, Inc. entered into a Material Definitive Agreement. The filing does not provide specific details on the agreement or any associated dollar amounts or parties involved.
Why It Matters
This filing indicates a significant event for Allarity Therapeutics, Inc., potentially impacting its operations or financial standing, though details are not yet disclosed.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could be significant, but the lack of specific details introduces uncertainty.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- March 19, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Allarity Therapeutics, Inc. on March 19, 2024?
The filing states that Allarity Therapeutics, Inc. entered into a Material Definitive Agreement on March 19, 2024, but does not provide specific details about the agreement itself.
Are there any specific dollar amounts mentioned in relation to the Material Definitive Agreement?
No, the provided filing excerpt does not mention any specific dollar amounts associated with the Material Definitive Agreement.
Who are the other parties involved in the Material Definitive Agreement?
The filing does not disclose the names of any other parties involved in the Material Definitive Agreement.
What is the principal executive office address for Allarity Therapeutics, Inc.?
The principal executive offices of Allarity Therapeutics, Inc. are located at 24 School Street, 2nd Floor, Boston, MA 02108.
What is the telephone number for Allarity Therapeutics, Inc.?
The telephone number for Allarity Therapeutics, Inc. is (401) 426-4664.
Filing Stats: 1,205 words · 5 min read · ~4 pages · Grade level 13.3 · Accepted 2024-03-19 20:41:52
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
- $947,000 — ng an aggregate offering price of up to $947,000, subject to the terms and conditions of
- $75.0 million — ompany's public float equals or exceeds $75.0 million. In the event that, subsequent to the d
- $75.0 m — eld by non-affiliates equals or exceeds $75.0 million, then the one-third limitation on
- $30,000 — e Agreement, in an amount not to exceed $30,000. Additionally, pursuant to the terms of
- $2,500 — he Agreement in an amount not to exceed $2,500 in the aggregate for each such bring-do
Filing Documents
- ea0202127-8k_allarity.htm (8-K) — 43KB
- ea020212701ex5-1_allarity.htm (EX-5.1) — 7KB
- ea020212701ex10-1_allarity.htm (EX-10.1) — 219KB
- ex5-1_001.jpg (GRAPHIC) — 22KB
- 0001213900-24-024156.txt ( ) — 528KB
- allr-20240319.xsd (EX-101.SCH) — 3KB
- allr-20240319_lab.xml (EX-101.LAB) — 33KB
- allr-20240319_pre.xml (EX-101.PRE) — 22KB
- ea0202127-8k_allarity_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. Date: March 19, 2024 By: /s/ Thomas Jensen Thomas Jensen Chief Executive Officer 3